Idorsia Ltd. · SIX:IDIA
Idorsia — H1 2018 Earnings Presentation
25 slides from Idorsia's earnings presentation, July 2018
Slide 1: Idorsia – Reaching out for more
Idorsia – Reaching out for more Investor Webcast – Half Year Results – July 2018
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: More novel drugs – Inspiring potential
More novel drugs – Inspiring potential Jean-Paul Clozel, CEO
Slide 4: Highlights in 2018
Highlights in 2018 First patients Enrolled into the Phase 3 study with lucerastat for Fabry disease First patients First patients Enrolled into the Phase 3 study with Enrolled into the Phase 3 program aprocitentan for resistant with nemorexant for insomnia hypertension management Financing secured F
Slide 5: Idorsia Today
Idorsia Today >700 Highly qualified 11 professionals Compounds in the pipeline, with four progressing to late-stage development in 2018 Strong balance sheet > 550 State-of-the-art laboratory workspaces 5 Investor Webcast - Half Year Results | July 2018
Slide 6: Our Strategic Priorities
Our Strategic Priorities Deliver at least 1 three products to market 5 key priorities to ensure the company’s success over the next 2 Build a commercial organization 5 years 3 Bring Idorsia to profitability in a sustainable manner 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize
Slide 7: More in the pipeline – Promising compounds
More in the pipeline – Resistant hypertension Fabry disease Promising compounds Management Aprocitentan Lucerastat Glucosylceramide synthase inhibitor Vasospasm associated with aneurysmal Dual endothelin Status: Phase 3 subarachnoid Diversified and balanced pipeline: receptor antagonist hemorrhage (
Slide 8: Lucerastat for Fabry disease
Lucerastat for Fabry disease Orphan drug status granted in the US and EU Low molecular weight iminosugar Access to most tissues, including peripheral & central nervous system Inhibitor of glucosylceramide synthase Oral administration Highly soluble with complete absorption Renal excretion of unchang
Slide 9: Lucerastat for Fabry disease – Summary
Lucerastat for Fabry disease Summary • Fabry disease is a rare genetic disorder with limited therapeutic Fabry disease options and a high medical need Compound: Lucerastat • Lucerastat is a small molecule, oral monotherapy with the potential as a new treatment approach for patients with Fabry Mechan
Slide 10: Nemorexant for insomnia
Nemorexant for insomnia Rationale Brain penetrating The orexin system is involved in the regulation of sleep and arousal Potent dual orexin receptor antagonist at OX1 and OX2 receptors Dual orexin receptor antagonism specifically targets excessive alertness, in contrast to treatments of insomnia tha
Slide 11: Nemorexant for insomnia – Summary
Nemorexant for insomnia Summary • From preclinical to phase 2: translation of product properties − Promotes sleep and maintains a natural sleep architecture Insomnia − PK/PD profile optimized to combine effect during the night with Compound: Nemorexant low residual next morning plasma concentration/
Slide 12: Aprocitentan for resistant hypertension
Aprocitentan for resistant hypertension Rationale Partnered with Janssen Biotech, Inc. Orally-active, potent dual ETA and ETB receptor antagonist Low potential for drug-drug interaction Synergistic effect with other antihypertensive drugs (RAAS blockers) in Evidence of blockade of both animal models
Slide 13: Aprocitentan for resistant hypertension – Summary
Aprocitentan for resistant hypertension Summary • Aprocitentan has great potential in difficult to control Resistant hypertension hypertension – resistant hypertension – as an oral, once daily management treatment based on: Compound: Aprocitentan − Pathophysiology of resistant hypertension Mechanism
Slide 14: Clazosentan for cerebral vasospasm
Clazosentan for cerebral vasospasm ETA selective ERA Highly soluble ETA selective Highly soluble endothelin receptor antagonist >1’800 patients treated with clazosentan providing significant experience in vasospasm post-aSAH and a well documented safety profile Ideal for intravenous administration F
Slide 15: Clazosentan for cerebral vasospasm – Summary
Clazosentan for cerebral vasospasm Summary • Developed as intravenous infusion for prevention and treatment Cerebral vasospasm of cerebral vasospasm in patients who have suffered an aSAH Compound: Clazosentan • Has potential to prevent ischemic complications of cerebral vasoconstriction and to Mecha
Slide 16: More questions?
More questions? Replay our investor webcasts here: https://www.idorsia.com/investors/news- and-events/latest-pipeline-webcast 16 Investor Webcast - Half Year Results | July 2018
Slide 17: More energy – Growing and delivering
More energy – Growing and delivering André Muller, CFO
Slide 18: Operating results - 6 months
Operating results - 6 months HY 2018 Non-GAAP US-GAAP Financial results as of June 30, 2018 18 Investor Webcast - Half Year Results | July 2018
Slide 19: Net results
Net results HY 2018 Non-GAAP -139 US-GAAP -139 -16 -20 -4 Operating results Financial results Income Tax results Non-Controlling Net results Interests Financial results as of June 30, 2018 19 Investor Webcast - Half Year Results | July 2018
Slide 20: Cash flow
Cash flow HY 2018 14 3 -61 -77 Capex / other -11 -138 Working capital -2 -3 requirements -75 -67 Funds from operations -5 -141 Cash flow Cash flow Cash flow Q1 2018 Q2 2018 HY 2018 Financial results as of June 30, 2018 20 Investor Webcast - Half Year Results | July 2018
Slide 21: Liquidity
Liquidity HY 2018 1'091 949 250 Cash deposits 250 > 12 months 218 85 Cash deposits < 12 months Cash and 622 615 cash equivalents Liquidity @ Liquidity @ Dec 31, 2017 Jun 30, 2018 Financial results as of June 30, 2018 21 Investor Webcast - Half Year Results | July 2018
Slide 22: Cash raise in July 2018
Cash raise in July 2018 HY 2018 CHF 505 million raised Impact on share count 181.4 163.6 5.7 5.7 + 5.9 mio 44.6 38.7 Equity instruments Convertible Bond CHF 200 million Equity derivatives + 11.9 mio Issued common shares 131.0 119.1 New registered shares CHF 305 million @ June 30, 2018 Proforma Finan
Slide 23: Financial Guidance
Financial Guidance HY 2018 Unforeseen events and potential milestone expenses excluded, we expect non-GAAP operating expenses for 2018 to be around 390 million Swiss francs. 23 Investor Webcast - Half Year Results | July 2018
Slide 24: Executing the strategy
Executing the strategy Incredible progress made in first year! • Operational independence following demerger • Funding secured for the development of our pipeline • Unencumbered assets with full strategic flexibility • First patients enrolled into three Phase 3 studies • Enriched R&D pipeline Next p
Slide 25: Idorsia – A unique opportunity
Idorsia – A unique opportunity All key ingredients to reach out for more! People Strategy Pipeline • Entrepreneurial management • Deliver at least three products • Diversified mostly unencumbered and organization led by to market in the next 5 years clinical development pipeline Actelion founders •